VIP Peptide Evidence for Gabapentin Users: Immune and Autonomic Layers
What's breaking down if you have Gabapentin / pregabalin
The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.
Why VIP might help you
- You are reading about Gabapentin / pregabalin — what breaks down matters before any compound name.
- Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.
Why Gabapentin / pregabalin matters for you
- Drug: Gabapentin / pregabalin
- What it does: Masks neuropathic pain signal; does not repair nerve.
- Therefore for you: state whether this drug reduces load, suppresses a signal, or supports metabolism — and whether that helps or trades off repair for your condition.
How these fit together
Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- VIP → immune / autonomic
What the evidence actually shows
This is a count of what is in this ledger — not a claim about all research worldwide.
- Scientific sources catalogued (PubMed, trials, reviews): 3
- Claims tagged human evidence: 2
- Claims tagged preclinical (animal/lab): 2
- Claims tagged anecdotal: 0
- Reddit posts catalogued: 0
- X posts catalogued: 0
- Other anecdote sources (YouTube, Instagram, etc.): 0
- Total sources in chain: 4
Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.
Quantified confidence (this ledger): 0.4 / 1.00 — low–moderate — mostly preclinical
Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.
What scientists say
Vasoactive intestinal peptide (VIP) prevents experimental arthritis (source s5)
Summary of mouse collagen-induced arthritis study with VIP treatment.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
Effect of Vasoactive Intestinal Polypeptide on Development of Headache and Associated Symptoms (source s11)
Human RCT on VIP infusion effects in volunteers.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension (source s16)
Human measurement of VIP levels in disease vs controls.
Evidence type: Tagged human evidence in this ledger — check sample size and design.
---
Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.
Evidence ledger 5 · tier-ranked · API
Ask this article · 7 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.